Form 8-K - Current report:
SEC Accession No. 0001213900-24-095195
Filing Date
2024-11-07
Accepted
2024-11-07 09:10:43
Documents
14
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220315-8k_cadrenal.htm   iXBRL 8-K 27435
2 PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON NOVEMBER 7, 2024 ea022031501ex99-1_cadrenal.htm EX-99.1 24442
  Complete submission text file 0001213900-24-095195.txt   233608

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cvkd-20241107.xsd EX-101.SCH 3015
4 XBRL LABEL FILE cvkd-20241107_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cvkd-20241107_pre.xml EX-101.PRE 22359
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0220315-8k_cadrenal_htm.xml XML 3799
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 241433468
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)